Successful treatment of glioblastoma (GBM) is hampered by primary tumor recurrence after
surgical resection and poor prognosis, despite adjuvant radiotherapy and chemotherapy. In …

Overall survival of patients with newly diagnosed glioblastoma (GBM) remains dismal at 16
months with state-of-the-art treatment that includes surgical resection, radiation, and …

Among central nervous system tumors, Glioblastoma (GBM) is the most common, aggressive
and neurological destructive primary brain tumor in adults. Standard care therapy for GBM …

Background Carboplatin, an antineoplastic agent, binds DNA and enhances radiotherapy
(RT) effects. Carboplatin-loaded hydrogel (oxidized hyaluronic acid/adipic acid dihydrazide) …

Introduction Surgical resection and systemic chemotherapy with temozolomide remain the
mainstay for treatment of glioblastoma. However, many patients are not candidates for …

Glioblastoma (GBM) treatment includes, when possible, surgical resection of the tumor
followed by radiotherapy and oral chemotherapy with temozolomide, however recurrences …

Glioblastoma multiforme (GBM), a common malignant neurological tumor, has boundaries
indistinguishable from those of normal tissue, making complete surgical removal ineffective …

Glioblastoma is the most frequent primary malignant brain tumor in adults. Despite
treatments including surgery, radiotherapy and chemotherapy by oral Temozolomide (TMZ) …

Background: Glioblastoma is the most lethal primary brain malignancy in adults. Standard of
care treatment, consisting of temozolomide (TMZ) and adjuvant radiotherapy (RT), mostly …

New approaches to malignant glioma are being actively investigated. Local drug delivery
directly to the site of the tumor is one novel approach that has been approved by the US FDA …